Preparing for the NASH epidemic: A call to action.
暂无分享,去创建一个
C. Mantzoros | R. Eckel | K. Cusi | H. El‐Serag | S. Klein | Z. Younossi | E. Bugianesi | D. Kruger | J. Shubrook | S. Harrison | F. Kanwal | M. Rinella | Yamini Natarajan | Kim M Pfotenhauer | Z. Younossi | Kenneth Cusi | Jay H. Shubrook | Robert H Eckel | Elisabetta Bugianesi | Stephen A Harrison | Christos Mantzoros | Samuel Klein | Davida Kruger
[1] K. Cusi,et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. , 2020, The New England journal of medicine.
[2] S. Asch,et al. Development, Validation, and Evaluation of a Simple Machine Learning Model to Predict Cirrhosis Mortality , 2020, JAMA network open.
[3] F. Tacke,et al. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors , 2020, Nature Reviews Gastroenterology & Hepatology.
[4] K. Cusi,et al. Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. , 2020, Contemporary clinical trials.
[5] A. Mithal,et al. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial) , 2020, Diabetologia.
[6] V. Wong,et al. Fatigue and Pruritus in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: The Impact on Patient‐Reported Outcomes , 2020, Hepatology communications.
[7] N. Byrne,et al. The Effect of a Novel Low-Volume Aerobic Exercise Intervention on Liver Fat in Type 2 Diabetes: A Randomized Controlled Trial , 2020, Diabetes Care.
[8] C. Mantzoros,et al. The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease , 2020, Metabolism.
[9] M. Stepanova,et al. Nonalcoholic Steatohepatitis is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[10] V. Wong,et al. Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Non-alcoholic Steatohepatitis-related, Child-Pugh A Cirrhosis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[11] T. Cotter,et al. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease , 2020 .
[12] M. Clark,et al. Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[13] P. Bossuyt,et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. , 2020, Journal of hepatology.
[14] C. Thompson,et al. Effect of Aspiration Therapy on Obesity-Related Comorbidities: Systematic Review and Meta-Analysis , 2020, Clinical endoscopy.
[15] N. Bhala,et al. Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. , 2020, Gastroenterology.
[16] K. Cusi. A diabetologist’s perspective of non‐alcoholic steatohepatitis (NASH): Knowledge gaps and future directions , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[17] K. Cusi,et al. Non-Alcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know? , 2020, The American journal of medicine.
[18] K. Cusi. Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes , 2020, Diabetes Care.
[19] S. Asch,et al. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease , 2020, Hepatology.
[20] V. Wong,et al. Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease , 2020, Journal of gastroenterology and hepatology.
[21] M. Riddle,et al. Standards of Medical Care in Diabetes—2020 Abridged for Primary Care Providers , 2019, Clinical Diabetes.
[22] F. Tacke,et al. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. , 2020, Journal of hepatology.
[23] F. Violi,et al. Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[24] R. DeFronzo,et al. Insulin Resistance and Atherosclerosis: Implications for Insulin Sensitizing Agents. , 2019, Endocrine reviews.
[25] C. Mantzoros,et al. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: a proof of concept study. , 2019, Metabolism: clinical and experimental.
[26] R. Haidry,et al. Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results , 2019, JHEP reports.
[27] K. Cusi,et al. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes , 2019, Diabetes Care.
[28] O. Cummings,et al. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease , 2019, JAMA network open.
[29] O. Cummings,et al. Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. , 2019, The American journal of gastroenterology.
[30] L. Longworth,et al. Referral pathways for patients with NAFLD based on non‐invasive fibrosis tests: Diagnostic accuracy and cost analysis , 2019, Liver international : official journal of the International Association for the Study of the Liver.
[31] D. Thorburn,et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. , 2019, Journal of hepatology.
[32] K. Cusi,et al. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options , 2019, JHEP reports.
[33] V. Wong,et al. Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[34] Z. Younossi,et al. Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease , 2019, Hepatology communications.
[35] F. Tacke,et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis , 2019, Hepatology.
[36] K. Cusi,et al. Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial , 2019, Diabetes Care.
[37] T. Taddei,et al. Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis. , 2019, Gastroenterology.
[38] M. Anvari,et al. Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta‐analysis , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[39] K. Cusi,et al. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. , 2019, The lancet. Diabetes & endocrinology.
[40] Z. Younossi,et al. Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States , 2019, Hepatology.
[41] O. Cummings,et al. Vitamin E Improves Transplant‐Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis , 2020, Hepatology.
[42] Cezary Szmigielski,et al. Transfer learning with deep convolutional neural network for liver steatosis assessment in ultrasound images , 2018, International Journal of Computer Assisted Radiology and Surgery.
[43] Joseph K. Lim,et al. The Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease Outcomes , 2018, Clinical liver disease.
[44] E. Speliotes,et al. Treatment of Dyslipidemia in Common Liver Diseases , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[45] Z. Younossi,et al. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD) , 2018, Medicine.
[46] L. Serfaty. Management of patients with non‐alcoholic steatohepatitis (NASH) in real life , 2018, Liver international : official journal of the International Association for the Study of the Liver.
[47] Michael Charlton,et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.
[48] Rohit Loomba,et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease , 2017, Hepatology.
[49] K. Cusi,et al. Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[50] L. Henry,et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018, Nature Reviews Gastroenterology & Hepatology.
[51] P. Aschner. F1000Prime recommendation of Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. , 2017 .
[52] Siddharth Singh,et al. Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta‐analysis , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[53] Jasjit S. Suri,et al. Extreme Learning Machine Framework for Risk Stratification of Fatty Liver Disease Using Ultrasound Tissue Characterization , 2017, Journal of Medical Systems.
[54] V. Wong,et al. Laboratory parameter‐based machine learning model for excluding non‐alcoholic fatty liver disease (NAFLD) in the general population , 2017, Alimentary pharmacology & therapeutics.
[55] K. Cusi,et al. Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial , 2017, The Journal of clinical endocrinology and metabolism.
[56] H. Makhlouf,et al. Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease , 2017, Hepatology communications.
[57] V. Wong,et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis , 2017, Hepatology.
[58] K. Cusi,et al. Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease , 2017, Hepatology.
[59] I. Raz,et al. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes , 2017, Expert review of clinical pharmacology.
[60] F. Violi,et al. Under-prescription of statins in patients with non-alcoholic fatty liver disease. , 2017, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[61] T. Kawaguchi,et al. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. , 2017, Journal of hepatology.
[62] J. Gottdiener,et al. The association of lean and fat mass with all-cause mortality in older adults: The Cardiovascular Health Study. , 2016, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[63] K. Cusi,et al. Pharmacological management of nonalcoholic fatty liver disease. , 2016, Metabolism: clinical and experimental.
[64] L. Henry,et al. Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.
[65] S. Sookoian,et al. How Safe Is Moderate Alcohol Consumption in Overweight and Obese Individuals? , 2016, Gastroenterology.
[66] Rachel M. Brown,et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study , 2016, The Lancet.
[67] European Association for the Study of the Liver,et al. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.
[68] H. El‐Serag,et al. Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia , 2016, Digestive Diseases and Sciences.
[69] J. Hardies,et al. Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[70] E. Bugianesi,et al. Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander , 2015, Seminars in Liver Disease.
[71] S. Friedman,et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.
[72] F. Pattou,et al. Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. , 2015, Gastroenterology.
[73] Mats Fredrikson,et al. Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.
[74] Zhen Wang,et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[75] H. El‐Serag,et al. Nonalcoholic Fatty Liver Disease is Underrecognized in the Primary Care Setting , 2015, The American Journal of Gastroenterology.
[76] K. Cusi,et al. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease , 2015, Hepatology.
[77] H. Makhlouf,et al. Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) , 2013, Digestive Diseases and Sciences.
[78] James E. Nelson,et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease , 2012, Hepatology.
[79] Eliseo Guallar,et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta‐analysis , 2011, Hepatology.
[80] Sarah A. Moore,et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss , 2011, Gut.
[81] O. Cummings,et al. Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network , 2011, Hepatology International.
[82] B. Neuschwander‐Tetri,et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.
[83] Julien Vergniol,et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease , 2010, Hepatology.
[84] D. Reeds,et al. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. , 2009, Gastroenterology.
[85] J. Barkin. A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis , 2007 .
[86] J. Hardies,et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.
[87] K. Lundbaek,et al. European Association for the study of diabetes , 1969, Diabetologia.